Sirolimus in Conjunction With EYLEA (Aflibercept) Versus EYLEA Alone for Exudative AMD

Trial Profile

Sirolimus in Conjunction With EYLEA (Aflibercept) Versus EYLEA Alone for Exudative AMD

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Sirolimus (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top